Milestone Pharmaceuticals Inc. Increase (Decrease) in Interest Payable, Net
Milestone Pharmaceuticals Inc. (MIST) reported Increase (Decrease) in Interest Payable, Net of $33.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2024-05-13
- Milestone Pharmaceuticals Inc. increase (decrease) in interest payable, net for the quarter ending 2023-03-31 was $33.00K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month |
|---|---|
| 2023-03-31 | $33.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |